Title
Author
DOI
Article Type
Special Issue
Volume
Issue
Article Menu
Export Article
More by Authors Links
Article Data
- Views 2015
- Dowloads 105
Original Research
Open AccessThe role of 15-lipoxygenase-1 expression and its potential role in the pathogenesis of endometrial hyperplasia and endometrial adenocarcinomas
The role of 15-lipoxygenase-1 expression and its potential role in the pathogenesis of endometrial hyperplasia and endometrial adenocarcinomas
1Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, School of Medicine, Dicle University, Diyarbakır, Turkey
2Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Gulhane Military Medical Academy and Medical School, Ankara, Turkey
3Department of Obstetrics and Gynecology, Divısion of Minimally Invasive Gynecology and Research, The University of Texas Medical Branch, Galveston, TX, USA
4Department of Pathology, Parkland Hospital, Dallas, TX, USA
5Departments of Clinical Cancer Prevention, Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
*Corresponding Author(s): G.S. Kilic E-mail: gokilic@utmb.edu
Abstract
Purpose of Investigation: To investigate the presence of 15-lipoxygenase-1 (15-LOX-1) expression and its potential role in the pathogenesis of endometrial hyperplasia and endometrial adenocarcinomas. Materials and Methods: The authors investigated the presence of 15-LOX-1 expression in samples from patients diagnosed with normal endometrium (n = 12), endometrial hyperplasia (n = 12), and endometrial cancer (n = 12). The immunohistochemical stainings were scored by three independent pathologists. A Western blot of 15- LOX-1 determined the presence of protein expression in normal endometrium. A Kolmogorov–Smirnov test was used to evaluate the data's distribution pattern. For pairwise comparisons of the combined scores between groups, the Mann-Whitney U test was used. Results: Based on the combined scores for 15-LOX-1 expression, strong immunochemistry staining was observed in samples diagnosed with normal endometrium. There was a significant difference in 15-LOX-1 expression between normal endometrium and endometrial adenocarcinoma (p = 0.03). Comparing tissues from normal endometrium and endometrial hyperplasia, there was a decline in the expression from normal endometrium to endometrial hyperplasia. However, the difference was not statistically significant. Conclusion: The present results show that a decrease of 15-LOX-1 expression in the endometrial tumorigenesis process, starting from normal endometrium to hyperplasia and endometrial cancer, might be a trigger. Further studies are required to determine its potential use as a marker in a larger randomized multicenter study.
Keywords
15-LOX-1, Endometrial hyperplasia; Endometrial adenocarcinomas.
Cite and Share
M.E. Sak,I. Alanbay,A. Rodriguez,T. Gokaslan,M. Borahay,I. Shureiqi,G.S. Kilic. The role of 15-lipoxygenase-1 expression and its potential role in the pathogenesis of endometrial hyperplasia and endometrial adenocarcinomas. European Journal of Gynaecological Oncology. 2016. 37(1);36-40.
References
[1] Siegel R., Naishadham D., Jemal A.: “Cancer statistics, 2013”. CA Cancer J. Clin., 2013, 63, 11.
[2] Bokhman J.V.: “Two pathogenetic types of endometrial carcinoma”. Gynecol. Oncol., 1983, 15, 10.
[3] Felix A.S., Weissfeld J.L., Stone R.A., Bowser R., Chivukla A., Edwards R.P., Linkov F.: “Factors associated with Type I and Type II endometrial cancer”. Cancer Causes Control, 2010, 21, 1851.
[4] Kurman R.J., Kaminski P.F., Norris H.J.: “The behavior of endometrial hyperplasia: a long-term study of "untreated" hyperplasia in 170 patients”. Cancer, 1985, 56, 403.
[5] Baer A.N., Costello P.B., Green F.A.: “In vivo activation of an omega-6 oxygenase in human skin”. Biochem. Biophys. Res. Commun., 1991, 180, 98.
[6] Brash A.R., Boeglin W.E., Chang M.S.: “Discovery of a second 15Slipoxygenase in humans”. Proc. Natl. Acad. Sci. U. S. A., 1997, 94, 6148.
[7] Serhan C.N., Jain A., Marleau S., Clish C., Kantarci A., Behbehani B., et al.: “Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators”. J. Immunol., 2003, 171, 6856.
[8] Ariel A., Li P.L., Wang W., Tang W.X., Fredman G., Hong S., et al.: “The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering”. J. Biol. Chem., 2005, 280, 43079.
[9] Shureiqi I., Wojno K.J., Poore J.A., Reddy R.G., Moussalli M.J., Spindler S.A., et al.: “Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-ipoxygenase-1 expression in human colon cancers”. Carcinogenesis, 1999, 20, 1985.
[10] Nixon J.B., Kim K.S., Lamb P.W., Bottone F.G., ElingT.E.: “15-Lipoxygenase-1 has anti-tumorigenic effects in colorectal cancer”. Prostaglandins Leukot. Essent. Fatty Acids, 2004, 70, 7.
[11] Heslin M.J., Hawkins A., Boedefeld W., Arnoletti J.P., Frolov A., Soong R., et al.: “Tumor-associated down-regulation of 15-lipoxygenase-1 is reversed by celecoxib in colorectal cancer”. Ann. Surg., 2005, 241, 941.
[12] Moussalli M.J., Wu Y., Zuo X., Yang X.L., Wistuba I.I., Raso M.G., et al.: “Mechanistic contribution of ubiquitous 15-lipoxygenase-1 expression loss in cancer cells to terminal cell differentiation evasion”. Cancer Prev. Res. (Phila.), 2011, 4, 1961.
[13] Shureiqi I., Xu X., Chen D., Lotan R., Morris J.S., Fischer S.M., Lippman S.M.: “Nonsteroidal anti-inflammatory drugs induce apoptosis in esophagealcancer cells by restoring 15-lipoxygenase-1 expression”. Cancer Res., 2001, 61, 4879.
[14] Jiang W.G., Watkins G., Douglas-Jones A., Mansel R.E.: “Reduction ofisoforms of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in human breast cancer”. Prostaglandins Leukot. Essent. Fatty Acids, 2006, 74, 235.
[15] Hennig R., Kehl T., Noor S., Ding X.Z., Rao S.M., Bergmann F., et al.: “15-lipoxygenase-1 production is lost in pancreatic cancer and overex-pression of the gene inhibits tumor cell growth”. Neoplasia, 2007, 9, 917.
[16] Zuo X., Peng Z., Wu Y., Moussalli M.J., Yang X.L., Wang Y., et al.: “Effects of guttargeted 15-LOX-1 transgene expression on colonic tumorigenesis in mice”. J. Natl. Cancer Inst., 2012, 104, 709.
[17] Zuo X., Shen L., Issa J.P., Moy O., Morris J.S., Lippman S.M., Shureiqi I.: “15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation”. FASEB J., 2008, 22, 1981.
[18] Bradford M.: “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding”. Anal. Biochem., 1976, 72, 248.
[19] Boruban M.C., Altundag K., Kilic G.S., Blankstein J.: “From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures”. Eur. J. Cancer Prev., 2008, 17, 133.
[20] Kilic G., Gurates B., Garon J., Kang H., Arun B., Lampley C.E., et al.: “Expression of cyclooxygenase-2 in endometrial adenocarci-noma”. Eur. J. Gynaecol. Oncol., 2005, 26, 271.
[21] Wu Y., Fang B., Yang X.Q., Wang L., Chen D., Krasnykh V., et al.: “Therapeutic molecular targeting of 15-lipoxygenase-1 in colon cancer”. Mol. Ther., 2008, 16, 886.
[22] Shureiqi I., Zuo X., Broaddus R., Wu Y., Guan B., Morris J.S., Lippman S.M.: “The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer”. FASEB J., 2007, 21, 743.
[23] Shureiqi I., Jiang W., Fischer S.M., Xu X., Chen D., Lee J.J., et al.: “GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells”. Cancer. Res., 2002, 62, 1178.
Submission Turnaround Time
Top